In this episode of “Blood Cancer Talks,” the hosts are joined by Dr. Horwitz of the Memorial Sloan Kettering Cancer Center to discuss peripheral T-cell lymphoma (PTCL).
Dr. Horwitz and the hosts specifically focus on PTCL–not otherwise specified, angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large cell lymphoma (ALCL). They discuss the ECHELON-2 randomized trial of CHOP versus BV-CHP in CD30-positive PTCL and the phase III Ro-CHOP study of romidepin-CHOP versus CHOP.
They also highlight a randomized controlled trial that compared autologous and allogeneic hemopoietic stem cell transplantation as part of frontline therapy in patients with poor-risk PTCL. Additionally, they discuss a phase II biomarker-driven study of ruxolitinib in T-cell lymphomas and the JACKPOT8 study.
This podcast originally appeared on Blood Cancer Talks.